Non-small cell lung cancer · line 1 · Pembrolizumab + carboplatin + paclitaxel (squamous NSCLC, first line)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-PEMBRO-CARBO-PACLITAXEL-NSCLC-SQ |
| ID | IND-NSCLC-SQ-PEMBRO-CARBO-PACLITAXEL-1L |
|---|---|
| Type | Indication |
| Status | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-KEYNOTE-407-PAZ-ARES-2018 SRC-KEYTRUDA-USPI-2026 |
Notes
Draft route, not clinically signed off. Trial population ECOG 0-1. No PD-L1 >=1% requirement. Organ function, autoimmune disease, immunosuppression, pregnancy, neuropathy and other contraindications still require independent clinician assessment. Driver-negative confirmation must come from the actual molecular assessment, not be inferred from missing results.
Used By
Algorithms
ALGO-NSCLC-METASTATIC-1L- ALGO-NSCLC-METASTATIC-1L